Vardenafil in Erectile Dysfunction: The Evidence of Its Therapeutic Value | Zendy

Kevin R. Rice | Zendy; Robert C. Dean | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vardenafil in Erectile Dysfunction: The Evidence of Its Therapeutic Value

Author(s) -

Kevin R. Rice,

Robert C. Dean

Publication year - 2010

Publication title -

clinical medicine insights therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.205

H-Index - 9

ISSN - 1179-559X

DOI - 10.4137/cmt.s3787

Subject(s) - vardenafil , erectile dysfunction , medicine , cgmp specific phosphodiesterase type 5 , prostate cancer , sildenafil , pharmacodynamics , diabetes mellitus , pharmacokinetics , pharmacology , urology , intensive care medicine , cancer , tadalafil , endocrinology

Erectile dysfunction (ED) is a condition that affects approximately 18 million American men. Phosphodiesterase-5 inhibitors (PDE5i’s) have revolutionized the treatment of erectile dysfunction by providing the first highly-effective oral medication. Vardenafil is one of 3 PDE5i’s commercially available for the treatment of ED in the United States. It has demonstrated therapeutic efficacy in the management of uncomplicated ED as well as more refractory cases associated with diabetes and surgery for prostate cancer. The physiology, pharmacokinetics, pharmacodynamics, and primary literature evaluating vardenafil are reviewed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research